Antimicrobial Therapy for Clostridioides difficile Infection
For initial CDI, use fidaxomicin 200 mg twice daily for 10 days as first-line therapy; vancomycin 125 mg four times daily for 10 days is an acceptable alternative, but metronidazole should only be used when neither fidaxomicin nor vancomycin are available. 1
Initial Episode Treatment Algorithm
Non-Severe CDI (WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL)
- Preferred: Fidaxomicin 200 mg twice daily for 10 days 1
- Alternative: Vancomycin 125 mg four times daily for 10 days 1
- Last resort only: Metronidazole 500 mg three times daily for 10-14 days (only if fidaxomicin and vancomycin unavailable) 1
The 2021 IDSA/SHEA guidelines represent a major shift away from metronidazole due to concerns about resistance and inferior efficacy 1, 2. Both IDSA/SHEA and ESCMID now prioritize fidaxomicin based on its superior ability to prevent recurrence, which is critical for long-term patient outcomes 3, 2.
Severe CDI (WBC >15,000 cells/μL OR serum creatinine ≥1.5 mg/dL)
- Preferred: Fidaxomicin 200 mg twice daily for 10 days 1
- Alternative: Vancomycin 125 mg four times daily for 10 days 1
The same regimens apply for severe disease, as the 2021 guidelines no longer differentiate dosing based on severity for non-fulminant cases 1.
Fulminant CDI (Hypotension/shock, ileus, or megacolon)
This is a medical emergency requiring aggressive combination therapy:
- Vancomycin 500 mg four times daily by mouth or nasogastric tube 1
- PLUS intravenous metronidazole 500 mg every 8 hours (particularly critical if ileus present) 1
- If ileus present: Add rectal vancomycin instillation (500 mg in 100-500 mL saline every 6 hours as retention enema) 1
Critical pitfall: Do not rely on oral antibiotics alone when ileus is present—the medication cannot reach the colon. IV metronidazole achieves colonic levels through inflamed mucosa, and rectal vancomycin provides direct delivery 1. ESCMID guidelines also endorse fidaxomicin and tigecycline as combination options for severe-complicated disease, representing an important evolution in management 3.
Recurrent CDI Management
First Recurrence
- Preferred: Fidaxomicin 200 mg twice daily for 10 days, OR extended regimen (twice daily for 5 days, then once every other day for 20 days) 1
- Alternative: Vancomycin tapered and pulsed regimen (125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks) 1
- Consider bezlotoxumab 10 mg/kg IV once during antibiotic treatment to prevent further recurrence, especially in high-risk patients (age >65, immunocompromised, severe disease) 1
Important caveat: Bezlotoxumab should be used cautiously in patients with congestive heart failure per FDA warning 1.
Second or Subsequent Recurrence
At this stage, you must escalate beyond standard antibiotics:
- Preferred: Fidaxomicin (standard or extended regimen) 1
- OR: Vancomycin tapered/pulsed regimen 1
- OR: Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days 1
- OR: Fecal microbiota transplantation (FMT) 1, 2
The panel recommends attempting at least 2 antibiotic treatment courses (meaning 3 total CDI episodes) before offering FMT 1. However, ESCMID guidelines now favor FMT or bezlotoxumab for second recurrence, reflecting the shift toward earlier microbiota restoration 2, 4.
Key Clinical Considerations
Stop the inciting antibiotic immediately if CDI develops during treatment for another infection—this is foundational to all CDI management 5.
Risk stratification matters: Patients with age >65 years, immunosuppression, inflammatory bowel disease, or severe disease presentation have higher recurrence risk and should be considered for bezlotoxumab even with initial episodes 1, 4.
Surgical consultation is mandatory for fulminant disease: If patients fail to improve within 48-72 hours despite maximal medical therapy, consider loop ileostomy with colonic lavage or subtotal colectomy 6. Mortality with fulminant CDI can reach 20% with certain ribotypes, making early surgical evaluation critical 7.
Do not treat asymptomatic colonization: Diagnosis requires both clinical symptoms (diarrhea) AND laboratory evidence of toxigenic C. difficile 5, 8. Testing asymptomatic patients leads to unnecessary treatment and potential harm.
The evidence strongly supports fidaxomicin as superior first-line therapy across all disease severities for initial episodes, with the primary advantage being reduced recurrence rates rather than improved initial cure 2. For fulminant disease, the combination of high-dose vancomycin plus IV metronidazole remains standard based on the 2021 IDSA/SHEA guidelines 1, though emerging data suggest fidaxomicin and tigecycline combinations may offer alternatives 3.